News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Paolo Tarantino: ACE-Breast-02 is the first phase 3 trial testing a site-specific ADC
Paolo Tarantino/X
Feb 19, 2025, 10:38

Paolo Tarantino: ACE-Breast-02 is the first phase 3 trial testing a site-specific ADC

Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper by Xichun Hu et al., titled “ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer” published on Signal Transduction and Targeted Therapy.

Authors: Xichun Hu, Qingyuan Zhang, Leiping Wang, Jian Zhang, Quchang Ouyang, Xiaojia Wang, Wei Li, Weimin Xie, Zhongsheng Tong, Shusen Wang, Faliang Xu, Tao Sun, Wei Liu, Zhendong Chen, Jinsheng Wu, Ying Wang, Haixia Wang, Min Yan, Xinshuai Wang, Jingfen Wang, Feilin Cao, Yingying Du, Yongqiang Zhang, Lilin Chen, Yuan Lei

Paolo Tarantino: ACE-Breast-02 is the first phase 3 trial testing a site-specific ADC

“ACE-Breast-02 is the first phase 3 trial testing a site-specific ADC. In AB-02, ARX788 improved PFS vs cape/lapatinib for HER2+ MBC, yet at the expense of high rate of ocular tox (>50%), hepatotoxicity (>70%) and ILD (>30%). ADC stability ≠ tolerability.”

Breast Cancer cancer Jian Zhang Leiping Wang OncoDaily Oncology Paolo Tarantino Qingyuan Zhang Quchang Ouyang Signal Transduction and Targeted Therapy Wei Li Weimin Xie Xiaojia Wang Xichun Hu Zhongsheng Tong
Special Coverage
Blog
May 10, 2025, 22:44
New postdoc opportunity at IARC studying the causes of cancer in diverse populations
Blog
May 10, 2025, 21:51
Join Dana-Farber’s Breast Oncology Center for a day of finding balance through wellness, education and community
Blog
May 10, 2025, 20:06
Zainab Shinkafi-Bagudu Honors UICC President Ulrika Årehed Kågström on Her Birthday
Blog
May 10, 2025, 19:24
Dato' Dr Saunthari Somasundaram: I had the privilege of speaking with Anita Abu Bakar on a topic close to both our hearts
Blog
May 10, 2025, 19:04
Elizabeth Ugwoma Awo-Ejeh: Mental stress is something we hardly talk about, yet it's something almost everyone carries
Insight
May 10, 2025, 18:11
Digestive Cancers Europe highlights Sara Ben Hmido’s study on patient perspectives of AI in surgical decision-making
Blog
May 10, 2025, 18:03
April Dorenbosch discussed migrant struggles with cancer care in Europe in Youth Cancer Europe interview
Insight
May 10, 2025, 17:56
David Planchard discussed EGFR-mutated NSCLC and clinical research developments with chinese colleagues
Blog
May 10, 2025, 17:48
Manette Le Grange Highlights ACT for Children Initiative in Pediatric Cancer Care
Blog
May 10, 2025, 17:44
Ashish Shah Explores Viral Mimicry Approach to Glioblastoma at Sylvester Comprehensive Cancer Center
Societies
May 10, 2025, 17:43
LUNGevity Foundation: Upal Basu Roy on progress in Small Cell Lung Cancer research
Science
May 10, 2025, 17:34
Galip Can Uyar: Prediction of 90-day Mortality Among Cancer Patients with Unplanned Hospitalisation